These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 28634535)

  • 1. Effectiveness and safety of daptomycin in patients with infective endocarditis undergoing heart valve replacement: a subgroup analysis from real-world data.
    Guleri A; Utili R; Dohmen P; Hamed K
    Ther Adv Infect Dis; 2017 Mar; 4(2):41-47. PubMed ID: 28634535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daptomycin for the Treatment of Infective Endocarditis: Results from European Cubicin(®) Outcomes Registry and Experience (EU-CORE).
    Guleri A; Utili R; Dohmen P; Petrosillo N; Piper C; Pathan R; Hamed K
    Infect Dis Ther; 2015 Sep; 4(3):283-96. PubMed ID: 26168988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Effectiveness and Safety of High-Dose Daptomycin: Results from Patients Included in the European Cubicin(®) Outcomes Registry and Experience.
    Seaton RA; Menichetti F; Dalekos G; Beiras-Fernandez A; Nacinovich F; Pathan R; Hamed K
    Adv Ther; 2015 Dec; 32(12):1192-205. PubMed ID: 26610384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world daptomycin use across wide geographical regions: results from a pooled analysis of CORE and EU-CORE.
    Seaton RA; Gonzalez-Ruiz A; Cleveland KO; Couch KA; Pathan R; Hamed K
    Ann Clin Microbiol Antimicrob; 2016 Mar; 15():18. PubMed ID: 26976128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Daptomycin for the treatment of infective endocarditis: results from a European registry.
    Dohmen PM; Guleri A; Capone A; Utili R; Seaton RA; González-Ramallo VJ; Pathan R; Heep M; Chaves RL
    J Antimicrob Chemother; 2013 Apr; 68(4):936-42. PubMed ID: 23190763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Daptomycin in the Clinical Setting: 8-Year Experience with Gram-positive Bacterial Infections from the EU-CORE(SM) Registry.
    Gonzalez-Ruiz A; Gargalianos-Kakolyris P; Timerman A; Sarma J; José González Ramallo V; Bouylout K; Trostmann U; Pathan R; Hamed K
    Adv Ther; 2015 Jun; 32(6):496-509. PubMed ID: 26108157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis.
    Kullar R; Casapao AM; Davis SL; Levine DP; Zhao JJ; Crank CW; Segreti J; Sakoulas G; Cosgrove SE; Rybak MJ
    J Antimicrob Chemother; 2013 Dec; 68(12):2921-6. PubMed ID: 23928022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daptomycin for the treatment of osteomyelitis and orthopaedic device infections: real-world clinical experience from a European registry.
    Malizos K; Sarma J; Seaton RA; Militz M; Menichetti F; Riccio G; Gaudias J; Trostmann U; Pathan R; Hamed K
    Eur J Clin Microbiol Infect Dis; 2016 Jan; 35(1):111-8. PubMed ID: 26563898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Treatment of Complicated Skin and Soft Tissue Infections with Daptomycin: Results from a Large European Registry (EU-CORE).
    Cogo A; Gonzalez-Ruiz A; Pathan R; Hamed K
    Infect Dis Ther; 2015 Sep; 4(3):273-82. PubMed ID: 26168987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Daptomycin in the treatment of patients with infective endocarditis: experience from a registry.
    Levine DP; Lamp KC
    Am J Med; 2007 Oct; 120(10 Suppl 1):S28-33. PubMed ID: 17904948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daptomycin for Gram-positive Infections in Patients with Neutropenia: Clinical Experience from a European Outcomes Registry.
    Keil F; Daikos GL; Skoutelis A; Dominguez JI; Pathan R; Hamed K
    Adv Ther; 2015 Aug; 32(8):715-26. PubMed ID: 26239201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose daptomycin therapy for left-sided infective endocarditis: a prospective study from the international collaboration on endocarditis.
    Carugati M; Bayer AS; Miró JM; Park LP; Guimarães AC; Skoutelis A; Fortes CQ; Durante-Mangoni E; Hannan MM; Nacinovich F; Fernández-Hidalgo N; Grossi P; Tan RS; Holland T; Fowler VG; Corey RG; Chu VH;
    Antimicrob Agents Chemother; 2013 Dec; 57(12):6213-22. PubMed ID: 24080644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of daptomycin in complicated skin and skin-structure infections due to methicillin-sensitive and -resistant Staphylococcus aureus: results from the CORE Registry.
    Martone WJ; Lamp KC
    Curr Med Res Opin; 2006 Dec; 22(12):2337-43. PubMed ID: 17257448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and clinical outcomes when utilizing high-dose (> or =8 mg/kg) daptomycin therapy.
    Moise PA; Hershberger E; Amodio-Groton MI; Lamp KC
    Ann Pharmacother; 2009 Jul; 43(7):1211-9. PubMed ID: 19584384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daptomycin experience in critical care patients: results from a registry.
    Brown JE; Fominaya C; Christensen KJ; McConnell SA; Lamp KC
    Ann Pharmacother; 2012 Apr; 46(4):495-502. PubMed ID: 22454446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Experience with Daptomycin for the Treatment of Gram-positive Infections in Children and Adolescents.
    Syriopoulou V; Dailiana Z; Dmitriy N; Utili R; Pathan R; Hamed K
    Pediatr Infect Dis J; 2016 May; 35(5):511-6. PubMed ID: 26849158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes of patients receiving daptomycin for the treatment of Staphylococcus aureus infections and assessment of clinical factors for daptomycin failure: a retrospective cohort study utilizing the Cubicin Outcomes Registry and Experience.
    Sakoulas G; Brown J; Lamp KC; Friedrich LV; Lindfield KC
    Clin Ther; 2009 Sep; 31(9):1936-45. PubMed ID: 19843483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Daptomycin for methicillin-resistant Staphylococcus aureus diabetic foot infections.
    Joseph WS; Quast T; Cogo A; Crompton MG; Yoon MJ; Lamp KC; Culshaw D; Chaves RL
    J Am Podiatr Med Assoc; 2014 Mar; 104(2):159-68. PubMed ID: 24725036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-World Treatment of Enterococcal Infections with Daptomycin: Insights from a Large European Registry (EU-CORE).
    Lübbert C; Rodloff AC; Hamed K
    Infect Dis Ther; 2015 Sep; 4(3):259-71. PubMed ID: 26168986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and safety of daptomycin in complicated skin and soft-tissue infections and bacteraemia in clinical practice: results of a large non-interventional study.
    Gonzalez-Ruiz A; Beiras-Fernandez A; Lehmkuhl H; Dohmen PM; Loeffler J; Chaves RL
    Int J Antimicrob Agents; 2013 Apr; 41(4):372-8. PubMed ID: 23499225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.